| T11961 |
MBM-55S
|
2083624-07-9
|
98.38%
|
|
|
MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer ce...
|
| T2094 |
Danusertib
|
827318-97-8
|
98.44%
|
|
|
Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinase...
|
| T23128 |
PD180970
|
287204-45-9
|
98.47%
|
|
|
PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit. PD180970 can be used in studies...
|
| T11641 |
N-Desmethyl imatinib
|
404844-02-6
|
98.60%
|
|
|
N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.
|
| T25476 |
Gypsogenin
|
639-14-5
|
98.61%
|
|
|
Gypsogenin (639-14-5) is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.
|
| T10799 |
CHMFL-ABL-039
|
2304344-56-5
|
98.63%
|
|
|
CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloi...
|
| T78605 |
CpCDPK1/TgCDPK1-IN-1
|
1092788-23-2
|
98.71%
|
|
|
CpCDPK1/TgCDPK1-IN-1 is a potent dual inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infectio...
|
| T23182 |
PPY A
|
875634-01-8
|
98.77%
|
|
|
PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase (IC50 of 9 and 20 nM, respectively).PPY A also inhibits the growth of Bcr-Abl T315l mutant o...
|
| T17267 |
XL228
|
898280-07-4
|
98.92%
|
|
|
XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).
|
| T2415 |
PP121
|
1092788-83-4
|
99.19%
|
|
|
PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) , ...
|
| T2070 |
Agerafenib
|
1188910-76-0
|
99.23%
|
|
|
Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.
|
| T21785 |
AG957
|
140674-76-6
|
99.27%
|
|
|
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in ch...
|
| T3063 |
PD173955
|
260415-63-2
|
99.28%
|
|
|
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC...
|
| T3071 |
Olverembatinib
|
1257628-77-5
|
99.29%
|
|
|
Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
|
| T1754 |
ZM 306416
|
690206-97-4
|
99.31%
|
|
|
ZM 306416 (CB 676475), a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).
|
| T6057 |
URMC-099
|
1229582-33-5
|
99.32%
|
|
|
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
|
| T11916 |
Lyn-IN-1
|
887650-05-7
|
99.33%
|
|
|
Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and Lyn
|
| T4191 |
Multi-kinase inhibitor 1
|
778274-97-8
|
99.34%
|
|
|
Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.
|
| T63746 |
Vamotinib
|
1416241-23-0
|
99.34%
|
|
|
Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylati...
|
| T2802 |
Nocodazole
|
31430-18-9
|
99.34%
|
|
|
Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell c...
|
